BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current Trends in Cancer Immunotherapy. Biomedicines 2020;8:E621. [PMID: 33348704 DOI: 10.3390/biomedicines8120621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Kuang G, Zhang Q, Jia J, Yu Y. Freezing biological organisms for biomedical applications. Smart Medicine 2022. [DOI: 10.1002/smmd.20220034] [Reference Citation Analysis]
2 Phakham T, Boonkrai C, Wongtangprasert T, Audomsun T, Attakitbancha C, Saelao P, Muanwien P, Sooksai S, Hirankarn N, Pisitkun T. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development. Sci Rep 2022;12:17792. [PMID: 36273231 DOI: 10.1038/s41598-022-20560-6] [Reference Citation Analysis]
3 Monastirioti A, Papadaki C, Kalapanida D, Rounis K, Michaelidou K, Papadaki MA, Mavroudis D, Agelaki S. Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. Cancers 2022;14:4739. [DOI: 10.3390/cancers14194739] [Reference Citation Analysis]
4 Barchi JJ Jr. Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates. Front Immunol 2022;13:852147. [PMID: 35432351 DOI: 10.3389/fimmu.2022.852147] [Reference Citation Analysis]
5 Orzetti S, Tommasi F, Bertola A, Bortolin G, Caccin E, Cecco S, Ferrarin E, Giacomin E, Baldo P. Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. Int J Mol Sci 2022;23:3012. [PMID: 35328435 DOI: 10.3390/ijms23063012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Campos-Silva C, López-Borrego S, Felgueres MJ, Esteso G, Vales-Gomez M. NKG2D Ligands in Liquid Biopsy: The Importance of Soluble and Vesicle-Bound Proteins for Immune Modulation. Crit Rev Immunol 2022;42:21-40. [PMID: 36374819 DOI: 10.1615/CritRevImmunol.2022045263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vidya G. Recent trends in cancer immunotherapy: Pathways and inhibitors. Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology 2022. [DOI: 10.1016/b978-0-323-90461-2.00001-8] [Reference Citation Analysis]
9 Entonu ME, Ika MD, Emmanuel E, Barnabas CL, Gaiya DD, Udu SK. Drug repurposing: Recent advancements, challenges, and future therapeutics for cancer treatment. JBMOA 2022;10:26-30. [DOI: 10.15406/jbmoa.2022.10.00322] [Reference Citation Analysis]
10 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Zafar A, Hasan M, Tariq T, Dai Z. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies. Bioconjug Chem 2021. [PMID: 34793138 DOI: 10.1021/acs.bioconjchem.1c00437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhang X, Wang X, Wu T, Yin W, Yan J, Sun Y, Zhao D. Therapeutic potential of targeting LSD1/ KDM1A in cancers. Pharmacol Res 2021;:105958. [PMID: 34718134 DOI: 10.1016/j.phrs.2021.105958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Filin IY, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Recent Advances in Experimental Dendritic Cell Vaccines for Cancer. Front Oncol 2021;11:730824. [PMID: 34631558 DOI: 10.3389/fonc.2021.730824] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
14 Manescu Paltanea V, Paltanea G, Antoniac I, Vasilescu M. Magnetic Nanoparticles Used in Oncology. Materials (Basel) 2021;14:5948. [PMID: 34683540 DOI: 10.3390/ma14205948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 M. Gordon E, L. Angel N, T. Kim T, A. Brigham D, P. Chawla S, L. Hall F. Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy. Advances in Precision Medicine Oncology 2021. [DOI: 10.5772/intechopen.96664] [Reference Citation Analysis]
16 Xue S, Ma M, Bei S, Li F, Wu C, Li H, Hu Y, Zhang X, Qian Y, Qin Z, Jiang J, Feng L. Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer. Front Immunol 2021;12:702615. [PMID: 34322132 DOI: 10.3389/fimmu.2021.702615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Yoon SJ, Lee CB, Chae SU, Jo SJ, Bae SK. The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. Int J Mol Sci 2021;22:6932. [PMID: 34203237 DOI: 10.3390/ijms22136932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 2021;19:162. [PMID: 34090476 DOI: 10.1186/s12957-021-02272-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kim D, Kim KI, Baek SH. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J Biomed Sci 2021;28:41. [PMID: 34082769 DOI: 10.1186/s12929-021-00737-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
20 Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases 2021;9:20. [PMID: 33802788 DOI: 10.3390/diseases9010020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]